p53 mutation as a source of aberrant β-catenin accumulation in cancer cells

Tolga Cagatay, Mehmet Ozturk

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

β-catenin is involved in both cell-cell interactions and wnt pathway-dependent cell fate determination through its interactions with E-cadherin and TCF/LEF transcription factors, respectively. Cytoplasmic/nuclear levels of β-catenin are important in regulated transcriptional activation of TCF/LEF target genes. Normally, these levels are kept low by proteosomal degradation of β-catenin through Axin1- and APC-dependent phosphorylation by CKI and GSK-3β. Deregulation of β-catenin degradation results in its aberrant accumulation, often leading to cancer. Accordingly, aberrant accumulation of β-catenin is observed at high frequency in many cancers. This accumulation correlates with either mutational activation of CTNNB1 (β-catenin) or mutational inactivation of APC and Axin1 genes in some tumors. However, there are many tumors that display β-catenin accumulation in the absence of a mutation in these genes. Thus, there must be additional sources for aberrant β-catenin accumulation in cancer cells. Here, we provide experimental evidence that wild-type β-catenin accumulates in hepatocellular carcinoma (HCC) cells in association with mutational inactivation of p53 gene. We also show that worldwide p53 and β-catenin mutation rates are inversely correlated in HCC. These data suggest that inactivation of p53 is an important cause of aberrant accumulation of β-catenin in cancer cells.

Original languageEnglish (US)
Pages (from-to)7971-7980
Number of pages10
JournalOncogene
Volume21
Issue number52
DOIs
StatePublished - Nov 14 2002

Fingerprint

Catenins
Mutation
Neoplasms
TCF Transcription Factors
Hepatocellular Carcinoma
APC Genes
Glycogen Synthase Kinase 3
Wnt Signaling Pathway
p53 Genes
Mutation Rate
Cadherins
Cell Communication
Transcriptional Activation
Genes
Phosphorylation

Keywords

  • β-catenin
  • Hepatocellular carcinoma
  • Mutation
  • p53
  • wnt pathway

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

p53 mutation as a source of aberrant β-catenin accumulation in cancer cells. / Cagatay, Tolga; Ozturk, Mehmet.

In: Oncogene, Vol. 21, No. 52, 14.11.2002, p. 7971-7980.

Research output: Contribution to journalArticle

Cagatay, Tolga ; Ozturk, Mehmet. / p53 mutation as a source of aberrant β-catenin accumulation in cancer cells. In: Oncogene. 2002 ; Vol. 21, No. 52. pp. 7971-7980.
@article{98393ad53a594a3fa06d1779a80cbfe2,
title = "p53 mutation as a source of aberrant β-catenin accumulation in cancer cells",
abstract = "β-catenin is involved in both cell-cell interactions and wnt pathway-dependent cell fate determination through its interactions with E-cadherin and TCF/LEF transcription factors, respectively. Cytoplasmic/nuclear levels of β-catenin are important in regulated transcriptional activation of TCF/LEF target genes. Normally, these levels are kept low by proteosomal degradation of β-catenin through Axin1- and APC-dependent phosphorylation by CKI and GSK-3β. Deregulation of β-catenin degradation results in its aberrant accumulation, often leading to cancer. Accordingly, aberrant accumulation of β-catenin is observed at high frequency in many cancers. This accumulation correlates with either mutational activation of CTNNB1 (β-catenin) or mutational inactivation of APC and Axin1 genes in some tumors. However, there are many tumors that display β-catenin accumulation in the absence of a mutation in these genes. Thus, there must be additional sources for aberrant β-catenin accumulation in cancer cells. Here, we provide experimental evidence that wild-type β-catenin accumulates in hepatocellular carcinoma (HCC) cells in association with mutational inactivation of p53 gene. We also show that worldwide p53 and β-catenin mutation rates are inversely correlated in HCC. These data suggest that inactivation of p53 is an important cause of aberrant accumulation of β-catenin in cancer cells.",
keywords = "β-catenin, Hepatocellular carcinoma, Mutation, p53, wnt pathway",
author = "Tolga Cagatay and Mehmet Ozturk",
year = "2002",
month = "11",
day = "14",
doi = "10.1038/sj.onc.1205919",
language = "English (US)",
volume = "21",
pages = "7971--7980",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "52",

}

TY - JOUR

T1 - p53 mutation as a source of aberrant β-catenin accumulation in cancer cells

AU - Cagatay, Tolga

AU - Ozturk, Mehmet

PY - 2002/11/14

Y1 - 2002/11/14

N2 - β-catenin is involved in both cell-cell interactions and wnt pathway-dependent cell fate determination through its interactions with E-cadherin and TCF/LEF transcription factors, respectively. Cytoplasmic/nuclear levels of β-catenin are important in regulated transcriptional activation of TCF/LEF target genes. Normally, these levels are kept low by proteosomal degradation of β-catenin through Axin1- and APC-dependent phosphorylation by CKI and GSK-3β. Deregulation of β-catenin degradation results in its aberrant accumulation, often leading to cancer. Accordingly, aberrant accumulation of β-catenin is observed at high frequency in many cancers. This accumulation correlates with either mutational activation of CTNNB1 (β-catenin) or mutational inactivation of APC and Axin1 genes in some tumors. However, there are many tumors that display β-catenin accumulation in the absence of a mutation in these genes. Thus, there must be additional sources for aberrant β-catenin accumulation in cancer cells. Here, we provide experimental evidence that wild-type β-catenin accumulates in hepatocellular carcinoma (HCC) cells in association with mutational inactivation of p53 gene. We also show that worldwide p53 and β-catenin mutation rates are inversely correlated in HCC. These data suggest that inactivation of p53 is an important cause of aberrant accumulation of β-catenin in cancer cells.

AB - β-catenin is involved in both cell-cell interactions and wnt pathway-dependent cell fate determination through its interactions with E-cadherin and TCF/LEF transcription factors, respectively. Cytoplasmic/nuclear levels of β-catenin are important in regulated transcriptional activation of TCF/LEF target genes. Normally, these levels are kept low by proteosomal degradation of β-catenin through Axin1- and APC-dependent phosphorylation by CKI and GSK-3β. Deregulation of β-catenin degradation results in its aberrant accumulation, often leading to cancer. Accordingly, aberrant accumulation of β-catenin is observed at high frequency in many cancers. This accumulation correlates with either mutational activation of CTNNB1 (β-catenin) or mutational inactivation of APC and Axin1 genes in some tumors. However, there are many tumors that display β-catenin accumulation in the absence of a mutation in these genes. Thus, there must be additional sources for aberrant β-catenin accumulation in cancer cells. Here, we provide experimental evidence that wild-type β-catenin accumulates in hepatocellular carcinoma (HCC) cells in association with mutational inactivation of p53 gene. We also show that worldwide p53 and β-catenin mutation rates are inversely correlated in HCC. These data suggest that inactivation of p53 is an important cause of aberrant accumulation of β-catenin in cancer cells.

KW - β-catenin

KW - Hepatocellular carcinoma

KW - Mutation

KW - p53

KW - wnt pathway

UR - http://www.scopus.com/inward/record.url?scp=0037079250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037079250&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1205919

DO - 10.1038/sj.onc.1205919

M3 - Article

C2 - 12439747

AN - SCOPUS:0037079250

VL - 21

SP - 7971

EP - 7980

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 52

ER -